title: Muscarinic mechanisms in psychotic disorders.
abstract: Schizophrenia is a devastating disease with several broad symptom clusters and the current monoamine-based treatments do not adequately treat the disease, especially negative and cognitive symptoms. A proposed alternative approach for treating schizophrenia is through the use of compounds that activate certain muscarinic receptor subtypes, the so-called muscarinic cholinergic hypothesis theory. This theory has been revitalized with a number of recent and provocative findings including postmortem reports in schizophrenia patients showing decreased numbers of muscarinic M(1) and M(4) receptors in brain regions associated with schizophrenia as well as decreased muscarinic receptors in an in vivo imaging study. Studies with M(4) knockout mice have shown that there is a reciprocal relationship between M(4) and dopamine receptor function, and a number of muscarinic agonists have shown antidopaminergic activity in a variety of preclinical assays predictive of antipsychotic efficacy in the clinic. Furthermore, the M(1)/M(4) preferring partial agonist xanomeline has been shown to have antipsychotic-like and pro-cognitive activity in preclinical models and in clinical trials to decrease psychotic-like behaviors in Alzheimer's patients and positive, negative, and cognitive symptoms in patients with schizophrenia. Therefore, we propose that an agonist with M(1) and M(4) interactions would effectively treat core symptom clusters associated with schizophrenia. Currently, research is focused on developing subtype-selective muscarinic agonists and positive allosteric modulators that have reduced propensity for parasympathetic side-effects, but retain the therapeutic benefit observed with their less selective predecessors.
authors.affiliation: Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, IN 46285, USA. dmckinzie@lilly.com
authors.forename: David L
authors.initials: DL
authors.lastname: McKinzie
authors.forename: Frank P
authors.initials: FP
authors.lastname: Bymaster
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D003071:Cognition; D055106:Genome-Wide Association Study; D006801:Humans; D018721:Muscarinic Agonists / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy / Q000209:etiology*; D011976:Receptors, Muscarinic / Q000032:analysis / Q000187:drug effects / Q000235:genetics / Q000502:physiology*
chemical_list: D014150:Antipsychotic Agents; D018721:Muscarinic Agonists; D011976:Receptors, Muscarinic